TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10808388

Group type: EXPERIMENTAL
Intervention: HRCT score for whole lung
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Percentage of lymphocytes HLA-DR in BAL from s.A
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Absolute number of CD25 in BAL from s.A
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Percentage of lymphocytes in BAL from s.B
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Percentage of HLA-DR lymphocytes in BAL from s.B
Number of subjects: 28
Study: 8526828

Group type: EXPERIMENTAL
Intervention: Dexedrine (10 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dexedrine
Number of subjects: 6
Study: 2191588

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 194

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Combination therapy (after initial monotherapy)
Number of subjects: 194
Study: 6999546

Group type: EXPERIMENTAL
Intervention: PGE2-gel (0.25 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PGE2-gel (0.05 mg, 3 ml)
Number of subjects: 100

Group type: COMPARATOR
Intervention: gel without PGE2
Number of subjects: 100
Study: 31258082

Group type: EXPERIMENTAL
Intervention: Constipation (cases)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control (no constipation)
Number of subjects: 167
Study: 29766004

Group type: EXPERIMENTAL
Intervention: Zataria multiflora (ZM) extracts
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26066587

Group type: EXPERIMENTAL
Intervention: High ascorbate group (HA) with plasma ascorbate levels >1 mmol/l
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low ascorbate group (LA) with plasma ascorbate levels <1 mmol/l
Number of subjects: 0
Study: 25281045

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) via three 5-minute cycles of upper limb ischemia using a blood pressure cuff
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (sham cuff)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 62
Study: 23034095

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) model with placement budgets of 25h, 40h, or 55h of job coach support.
Number of subjects: 100
Study: 21028984

Group type: EXPERIMENTAL
Intervention: CHG-impregnated cloths applied thrice weekly
Number of subjects: 1562

Group type: COMPARATOR
Intervention: Control cloths (Comfort Bath; Sage) applied thrice weekly
Number of subjects: 1562
Study: 17998082

Group type: EXPERIMENTAL
Intervention: Self-reported diabetes
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Self-reported hypertension
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Self-reported hypercholesterolemia
Number of subjects: 430

Group type: COMPARATOR
Intervention: Self-reporting of diabetes among Surinamese vs. Dutch indigenous patients
Number of subjects: 430
Study: 15204314

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-energy diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination low-fat/low-energy diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study: 11595689

Group type: EXPERIMENTAL
Intervention: Melanoma vaccine with gp100(280) peptide and tetanus helper peptide
Number of subjects: 22
Study: 9678294

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen 2.5 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen 5 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8270757

Group type: EXPERIMENTAL
Intervention: 30 g added barley bran flour
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 3 g added barley oil extract
Number of subjects: 79

Group type: COMPARATOR
Intervention: 20 g added cellulose (control)
Number of subjects: 79
Study: 2683024

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) chewable tablets at a dose of four tablets daily for 1 month
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 808195

Group type: EXPERIMENTAL
Intervention: Amino acid infusion at 1.7 gm/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amino acid infusion at 1.0 gm/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dextrose infusion
Number of subjects: 0
Study: 31618704

Group type: EXPERIMENTAL
Intervention: DPFC (cisplatin 40 mg/m2, docetaxel 40 mg/m2, 5-FU 2000 mg/m2, cetuximab 400/250 mg/m2)
Number of subjects: 180

Group type: COMPARATOR
Intervention: PFC (cisplatin 100 mg/m2, 5-FU 1000 mg/m2, cetuximab 400/250 mg/m2)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: DPFC
Number of subjects: 180

Group type: COMPARATOR
Intervention: PFC
Number of subjects: 180
Study: 29025834

Group type: EXPERIMENTAL
Intervention: Orsiro stent with biodegradable polymer
Number of subjects: 2152

Group type: COMPARATOR
Intervention: CX-ISAR stent (polymer-free)
Number of subjects: 2152

Group type: EXPERIMENTAL
Intervention: 3 months DAPT duration
Number of subjects: 2152

Group type: COMPARATOR
Intervention: 12 months DAPT duration
Number of subjects: 2152
Study: 25218668

Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/day by week 4, n = 38)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (n = 36)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 24283058

Group type: COMPARATOR
Intervention: T+M (2g BID tinidazole for two days and vaginal suppositories of 1000 mg metronidazole at day 1 and 3)
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: T+M+P (same as T+M plus topical administration of vaginal probiotic from day 5)
Number of subjects: 539

Group type: COMPARATOR
Intervention: T+M
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: T+M+P
Number of subjects: 539
Study: 21534846

Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment
Number of subjects: 246
Study: 19896572

Group type: EXPERIMENTAL
Intervention: Two-item questionnaire
Number of subjects: 117

Group type: COMPARATOR
Intervention: A/CS-12
Number of subjects: 117
Study: 16825681

Group type: EXPERIMENTAL
Intervention: Palm oil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Partially hydrogenated soybean oil
Number of subjects: 15

Group type: COMPARATOR
Intervention: Soybean oil
Number of subjects: 15

Group type: COMPARATOR
Intervention: Canola oil
Number of subjects: 15
Study: 12513955

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy for head and neck melanoma
Number of subjects: 2610

Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy for truncal melanoma
Number of subjects: 2610

Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy for extremity melanoma
Number of subjects: 2610
Study: 16957540

Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) + Electroconvulsive Therapy (ECT)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Vagus Nerve Stimulation (VNS)
Number of subjects: 205
Study: 10227615

Group type: EXPERIMENTAL
Intervention: Topiramate 6 mg/kg/day
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 8907570

Group type: EXPERIMENTAL
Intervention: Insertion of new shunts
Number of subjects: 34

Group type: COMPARATOR
Intervention: Dilatation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Explanted livers assessment
Number of subjects: 34
Study: 1684909

Group type: EXPERIMENTAL
Intervention: D-verapamil (DVPM) 800 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: D-verapamil (DVPM) 1200 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: D-verapamil (DVPM) 600 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: D-verapamil (DVPM) 150-300 mg 6 h
Number of subjects: 10
Study: 7043162

Group type: EXPERIMENTAL
Intervention: 5 or 10 g GABA (intervention)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 mg muscimol (intervention)
Number of subjects: 12
Study: 30606137

Group type: COMPARATOR
Intervention: Supervised group exercise (GROUP)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Home-based exercise (HOME)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Personal training (PT)
Number of subjects: 59
Study: 28653400

Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib and dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panobinostat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panobinostat and bortezomib
Number of subjects: 0
Study: 26467819

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (60-70% VO2peak for 45 min, 3 days per week) for 8 weeks
Number of subjects: 32
Study: 25091663

Group type: EXPERIMENTAL
Intervention: 116E rotavirus vaccine
Number of subjects: 6799

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6799
Study: 22751691

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 19669018

Group type: EXPERIMENTAL
Intervention: Modified fluid gelatin and normal saline (NS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 40
Study: 17317370

Group type: COMPARATOR
Intervention: Rosuvastatin 40 mg alone
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg + Ezetimibe 10 mg
Number of subjects: 469
Study: 15076156

Group type: EXPERIMENTAL
Intervention: Isoprenaline (Iso) 8 microg/kg per min
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (glucose 5%)
Number of subjects: 41
Study: 11274548

Group type: EXPERIMENTAL
Intervention: Triple-dose gadodiamide (0.3 mmol/kg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Single-dose gadodiamide (0.1 mmol/kg)
Number of subjects: 105
Study: 9737831

Group type: EXPERIMENTAL
Intervention: Azelaic acid 20% cream and glycolic acid lotion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tretinoin 0.025% cream
Number of subjects: 0
Study: 7913292

Group type: EXPERIMENTAL
Intervention: eformoterol 24 micrograms twice daily
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study: 30585747

Group type: EXPERIMENTAL
Intervention: Diet lemonade
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Regular lemonade
Number of subjects: 12

Group type: COMPARATOR
Intervention: Baseline (controlled diet only)
Number of subjects: 12
Study: 28323322

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia-hyperoxia training (IHHT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham-IHHT (breathing room air, O2 at 21%)
Number of subjects: 46
Study: 25617774

Group type: EXPERIMENTAL
Intervention: Male‐Trauma Recovery Empowerment Model (M‐TREM)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS) and Male‐Trauma Recovery Empowerment Model (M‐TREM)
Number of subjects: 230
Study: 24317380

Group type: EXPERIMENTAL
Intervention: HOMEfit exercise intervention
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: N4 patients (1,214) invited to final assessment
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: N5 patients (434) attended practice screening
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: N6 patients (209) randomized
Number of subjects: 209
Study: 21144515

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (200 μg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 40
Study: 18295465

Group type: EXPERIMENTAL
Intervention: Formula F11 (CH:AL, 20:80 IPC:Imwitor 900 K, 3:1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate release Ikorel tablet
Number of subjects: 0
Study: 16863527

Group type: EXPERIMENTAL
Intervention: Zinc sulfate 100 mg three times per day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 12645862

Group type: EXPERIMENTAL
Intervention: 50 mg lignocaine
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 100 mg lignocaine
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 150 mg lignocaine
Number of subjects: 153
Study: 11289670

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU, 2 doses at baseline, additional doses at 4 and 8 months)
Number of subjects: 687

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Breastfeeding for longer than 18 months
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Children over two years of age
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Children with repeated diagnoses of malaria
Number of subjects: 687
Study: 9316621

Group type: EXPERIMENTAL
Intervention: rhIL-1 beta (200 ng/kg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: rhIL-1 beta (postchemotherapy)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: rhIL-1 beta (all dose levels)
Number of subjects: 54
Study: 8451780

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) 300 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Imipramine 50 mg
Number of subjects: 6
Study: 3092053

Group type: EXPERIMENTAL
Intervention: Diazepam (tapered doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Placebo and Diazepam)
Number of subjects: 40
Study: 31699671

Group type: EXPERIMENTAL
Intervention: High CXCL9 expression
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: High CXCL9 expression in triple negative disease
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: High CXCL13 expression in luminal-HER2 disease
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Low CXCL13 and high CXCL9 expression
Number of subjects: 557
Study: 30830119

Group type: EXPERIMENTAL
Intervention: Choline alfoscerate (ChA) 14 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Succinate combination (SC) 0.5 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of ChA and SC
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 80
Study: 27062963

Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (GTE) 1500 mg daily for 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 80
Study: 24206233

Group type: EXPERIMENTAL
Intervention: Standard audiovisual interventions (experimental group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo audiovisual interventions (placebo group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 23200974

Group type: COMPARATOR
Intervention: Topical 2% lignocaine jelly
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1% lignocaine ICSB
Number of subjects: 40
Study: 20739853

Group type: EXPERIMENTAL
Intervention: Good glucose control (target glucose level of 130 mg/dL)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Poor glucose control (glucose levels above 130 mg/dL)
Number of subjects: 208
Study: 28438257

Group type: EXPERIMENTAL
Intervention: Test allopurinol tablet (300 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference allopurinol tablet (300 mg)
Number of subjects: 18
Study: 16168728

Group type: EXPERIMENTAL
Intervention: High-risk DAT1 ADHD group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low-risk DAT1 ADHD group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 42
Study: 12586856

Group type: EXPERIMENTAL
Intervention: Power training (PT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 39
Study: 10673880

Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Direct Laryngoscopy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Face Mask
Number of subjects: 60
Study: 8840352

Group type: EXPERIMENTAL
Intervention: Arecoline 1 mg/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Arecoline 4 mg/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Arecoline 16 mg/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Arecoline 28 mg/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Arecoline 40 mg/day
Number of subjects: 9
Study: 1751666

Group type: EXPERIMENTAL
Intervention: Fibrous carbon enterosorbent VESTA in tablets for 14 days (group I)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Parenteral administration of hemostimulants, hemosubstitutes and detoxicants (group II)
Number of subjects: 46
Study: 6818596

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 12.5 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 25.0 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no chlorpromazine)
Number of subjects: 25
Study: 30205242

Group type: EXPERIMENTAL
Intervention: OCT-guided stent implantation
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Standard angiographic-guided implantation
Number of subjects: 1200
Study: 26803719

Group type: EXPERIMENTAL
Intervention: Experimental arm (NRTIs withdrawn)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control arm (NRTIs maintained)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 90
Study: 23685919

Group type: EXPERIMENTAL
Intervention: Custom contoured shapes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Commercially shaped cushion
Number of subjects: 30
Study: 22811499

Group type: EXPERIMENTAL
Intervention: Patient-centered adherence intervention
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study: 20643092

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 433
Study: 18543380

Group type: EXPERIMENTAL
Intervention: 30 min Qigong exercise
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 60 min Qigong exercise
Number of subjects: 41
Study: 15813835

Group type: EXPERIMENTAL
Intervention: Capsules taken just before meals (schedule A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Capsules taken just after meals (schedule B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Capsules taken along with meals (schedule C)
Number of subjects: 24
Study: 12748463

Group type: EXPERIMENTAL
Intervention: EE/levonorgestrel (0.3 mg ethinyl estradiol / 0.15 mg levonorgestrel)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: EE/desogestrel (0.3 mg ethinyl estradiol / 0.15 mg desogestrel)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: EE/desogestrel
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: EE/levonorgestrel
Number of subjects: 34
Study: 11097672

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 10
Study: 8792107

Group type: EXPERIMENTAL
Intervention: Micral-Test strip
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Pooled Micral-Test result (> or = 15 mg/l)
Number of subjects: 530
Study: 1352370

Group type: COMPARATOR
Intervention: RU 42 173 (0.25 mg single oral dose)
Number of subjects: 12
Study: 6397914

Group type: EXPERIMENTAL
Intervention: Herbal combination Dietosan (species)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Herbal combination Dietosan (disperg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Herbal combination Dietosan (species) with glybenclamide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Herbal combination Dietosan (disperg) with glybenclamide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Herbal combination Dietosan (species and disperg)
Number of subjects: 40
Study: 30964820

Group type: EXPERIMENTAL
Intervention: Oropharyngeal colostrum administration (0.2 mL every 2 hours for 48 hours)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (sterile water, 0.2 mL every 2 hours for 48 hours)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Oropharyngeal colostrum administration
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 113
Study: 28372580

Group type: EXPERIMENTAL
Intervention: Clinical decision-making support system (CDMSS) using USSD-based text messaging of standard emergency obstetric and neonatal protocols.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 16
Study: 27223302

Group type: EXPERIMENTAL
Intervention: Dark chocolate (65 g)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Yerba mate (3 g)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Chocolate-placebo
Number of subjects: 92

Group type: COMPARATOR
Intervention: Mate-placebo
Number of subjects: 92
Study: 23875574

Group type: EXPERIMENTAL
Intervention: Visual working memory load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial working memory load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phonological working memory load
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-task (no working memory load)
Number of subjects: 0
Study: 22424011

Group type: EXPERIMENTAL
Intervention: Worsening renal function III (WRF III)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Worsening renal function I (WRF I)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Worsening renal function II (WRF II)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: High doses of loop diuretics and spironolactone use
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitor, angiotensin receptor blocker, and β‐blocker use
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Allocation to N‐terminal pro‐B‐type natriuretic peptide‐guided management
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Death, death or hospitalization, and death or HF hospitalization
Number of subjects: 566